Gene/NN
Expression/NN
Signatures/NNS
for/IN
Compound/NN
Response/NN
in/IN
Cancers/NNS
./.
====================
Recent/JJ
trends/NNS
in/IN
generating/VBG
multiple/JJ
,/,
largescale/JJ
datasets/NNS
provide/VBP
new/JJ
challenges/NNS
to/TO
manipulating/VBG
the/DT
relationship/NN
of/IN
different/JJ
types/NNS
of/IN
components/NNS
,/,
such/JJ
as/IN
gene/NN
expression/NN
and/CC
drug/NN
response/NN
data/NNS
./.
====================
Integrative/JJ
analysis/NN
of/IN
compound/NN
response/NN
and/CC
gene/NN
expression/NN
datasets/NNS
generates/VBZ
an/DT
opportunity/NN
to/TO
capture/NN
the/DT
possible/JJ
mechanism/NN
of/IN
compounds/NNS
by/IN
using/VBG
signature/JJ
genes/NNS
on/IN
diverse/JJ
types/NNS
of/IN
cancer/NN
cell/NN
lines/NNS
./.
====================
Here/RB
,/,
we/PRP
integrated/VBD
datasets/NNS
of/IN
compound/NN
response/NN
and/CC
gene/NN
expression/NN
profiles/NNS
on/IN
NCI60/NN
cell/NN
lines/NNS
and/CC
constructed/VBD
a/DT
network/NN
,/,
revealing/VBG
the/DT
relationship/NN
for/IN
801/CD
compounds/NNS
and/CC
341/CD
gene/NN
probes/NNS
./.
====================
As/IN
examples/NNS
,/,
obtusol/NN
,/,
which/WDT
shows/VBZ
an/DT
exclusive/JJ
sensitivity/NN
on/IN
a/DT
small/JJ
number/NN
of/IN
colon/NN
cell/NN
lines/NNS
,/,
is/VBZ
related/JJ
to/TO
a/DT
set/NN
of/IN
gene/NN
probes/NNS
that/DT
have/VBP
unique/JJ
overexpression/NN
in/IN
colon/NN
cell/NN
lines/NNS
./.
====================
We/PRP
also/RB
found/VBD
that/IN
the/DT
SLC7A11/NN
gene/NN
,/,
a/DT
direct/JJ
target/NN
of/IN
miR26b/JJ
,/,
might/MD
be/VB
a/DT
key/JJ
element/NN
in/IN
understanding/VBG
the/DT
action/NN
of/IN
many/JJ
diverse/JJ
classes/NNS
of/IN
anticancer/JJ
compounds/NNS
./.
====================
We/PRP
demonstrated/VBD
that/IN
this/DT
network/NN
might/MD
be/VB
useful/JJ
for/IN
studying/VBG
the/DT
mechanisms/NNS
of/IN
varied/VBN
compound/NN
response/NN
on/IN
diverse/JJ
cancer/NN
cell/NN
lines/NNS
./.
====================
Keywords/NNS
:/:
NCI60/CD
,/,
drug/NN
response/NN
,/,
gene/NN
expression/NN
,/,
integrating/VBG
,/,
networkThe/DT
interest/VBP
in/IN
studying/VBG
mechanisms/NNS
of/IN
compounds/NNS
and/CC
finding/NN
new/JJ
compounds/NNS
with/IN
better/RBR
efficacy/NN
than/IN
known/JJ
anticancer/JJ
drugs/NNS
has/VBZ
recently/RB
increased/VBN
due/JJ
to/TO
the/DT
decreasing/VBG
number/NN
and/CC
increasing/VBG
cost/RB
of/IN
newly/RB
released/VBN
anticancer/JJ
drugs/NNS
(/(
Xu/NNP
and/CC
Cote/NN
,/,
2011/CD
)/)
./.
====================
NCI60/CD
project/VB
as/IN
a/DT
predictive/JJ
model/NN
of/IN
drug/NN
response/NN
and/CC
gene/NN
expression/NN
was/VBD
developed/VBN
by/IN
the/DT
US/NN
National/JJ
Cancer/NN
Institute/JJ
(/(
NCI/NN
)/)
(/(
Shoemaker/NN
,/,
2006/CD
)/)
./.
====================
This/DT
panel/NN
of/IN
60/CD
cell/NN
lines/NNS
includes/VBZ
nine/CD
distinct/JJ
tumor/NN
types/NNS
:/:
leukemia/NN
(/(
LN/NN
)/)
,/,
colon/NN
(/(
CO/NN
)/)
,/,
lung/NN
(/(
nonsmall/JJ
cell/NN
lung/NN
cancer/NN
)/)
(/(
NSCLC/NN
)/)
,/,
CNS/NN
,/,
renal/JJ
(/(
REN/NN
)/)
,/,
melanoma/NN
(/(
ME/NNP
)/)
,/,
ovarian/JJ
(/(
OVR/NN
)/)
,/,
breast/NN
(/(
BR/NN
)/)
and/CC
prostate/NN
(/(
PRO/NN
)/)
(/(
Table/JJ
1/CD
)/)
(/(
Scudiero/NNP
et/FW
al./FW
,/,
1988/CD
)/)
./.
====================
From/IN
the/DT
Developmental/JJ
Therapeutics/NNS
Program/NN
(/(
DTP/NN
)/)
of/IN
NCI/NIH/NN
,/,
multiple/JJ
highthroughput/JJ
screening/VBG
data/NNS
are/VBP
available/JJ
,/,
including/VBG
drug/NN
response/NN
data/NNS
(/(
Weinstein/NNP
,/,
2006/CD
)/)
,/,
gene/NN
expression/NN
data/NNS
(/(
Blower/NNP
et/FW
al./FW
,/,
2007/CD
)/)
,/,
DNA/NN
copy/NN
number/NN
change/NN
data/NNS
(/(
Ikediobi/NNP
et/FW
al./FW
,/,
2006/CD
)/)
,/,
protein/NN
analysis/NN
(/(
Nishizuka/NNP
et/FW
al./FW
,/,
2003/CD
)/)
,/,
DNA/NN
methylation/NN
(/(
Ehrich/JJ
et/FW
al./FW
,/,
2008/CD
)/)
,/,
functional/JJ
target/NN
analysis/NN
(/(
Lee/NNP
et/FW
al/JJ
./.
====================
1994/CD
)/)
,/,
and/CC
reverse/JJ
phase/NN
protein/NN
array/NN
(/(
RPPA/NN
)/)
analysis/NN
(/(
Shankavaram/NN
et/FW
al./FW
,/,
2007/CD
)/)
and/CC
so/RB
on/IN
./.
====================
The/DT
NCI/NN
drug/NN
stock/NN
is/VBZ
made/VBN
of/IN
more/RBR
than/IN
100,000/CD
compounds/NNS
,/,
and/CC
the/DT
screening/NN
data/NNS
for/IN
more/RBR
than/IN
40,000/CD
compounds/NNS
is/VBZ
publicly/RB
available/JJ
(/(
http/NN
:/:
//dtp/JJ
./.
====================
cancer/NN
./.
====================
gov//DT
)/)
./.
====================
The/DT
cell/NN
line/NN
response/NN
to/TO
the/DT
compounds/NNS
is/VBZ
quantified/VBN
by/IN
GI50/NN
value，the/DT
concentration/NN
required/VBN
to/TO
inhibit/VB
the/DT
growth/NN
of/IN
an/DT
exposed/VBN
cell/NN
line/NN
culture/NN
to/TO
50/CD
%/NN
relative/JJ
to/TO
the/DT
untreated/JJ
control/NN
./.
====================
Recently/RB
,/,
the/DT
construction/NN
of/IN
biophysical/JJ
network/NN
models/NNS
of/IN
numerous/JJ
components/NNS
has/VBZ
contributed/VBN
to/TO
our/PRP$
understanding/NN
of/IN
the/DT
relationship/NN
between/IN
different/JJ
types/NNS
of/IN
biological/JJ
responses/NNS
(/(
Pe'er/NN
and/CC
Hacohen/NNP
,/,
2011/CD
)/)
./.
====================
A/DT
critical/JJ
question/NN
remaining/VBG
is/VBZ
how/WRB
to/TO
interpret/VB
the/DT
network/NN
and/CC
take/VBP
out/RP
the/DT
new/JJ
biological/JJ
insights/NNS
or/CC
knowledge/NN
./.
====================
Our/PRP$
approach/NN
to/TO
this/DT
question/NN
is/VBZ
to/TO
calculate/JJ
the/DT
simple/JJ
Pearson/NN
correlation/NN
coefficient/JJ
(/(
PCC/NN
)/)
(/(
Liu/NNP
et/FW
al./FW
,/,
2007/CD
)/)
(/(
Jobson/NNP
et/FW
al./FW
,/,
2007/CD
)/)
of/IN
drug/NN
response/NN
and/CC
gene/NN
expression/NN
profile/NN
over/IN
diverse/JJ
NCI60/NN
cell/NN
lines/NNS
./.
====================
It/PRP
is/VBZ
possible/JJ
to/TO
obtain/VB
a/DT
certain/JJ
number/NN
of/IN
significant/JJ
correlations/NNS
between/IN
gene/NN
expression/NN
and/CC
compound/NN
response/NN
on/IN
subsets/NNS
of/IN
cancer/NN
samples/NNS
./.
====================
In/IN
this/DT
research/NN
,/,
our/PRP$
goal/NN
is/VBZ
to/TO
create/VB
a/DT
global/JJ
network/NN
including/VBG
all/DT
known/VBN
compound/NN
data/NNS
and/CC
gene/NN
expression/NN
profiles/NNS
,/,
and/CC
to/TO
subtract/VB
specific/JJ
networks/NNS
of/IN
genes/NNS
and/CC
compounds/NNS
revealing/VBG
unique/JJ
mechanisms/NNS
of/IN
compound/NN
action/NN
./.
====================
Data/NNS
of/IN
compound/NN
response/NN
(/(
GI50/NN
)/)
on/IN
NCI60/NN
cell/NN
lines/NNS
was/VBD
downloaded/VBN
from/IN
the/DT
NCI/NN
Developmental/JJ
Therapeutics/NNS
Program/NN
(/(
DTP/NN
)/)
site/NN
(/(
www/NN
./.
====================
//dtp/RB
./.
====================
nci/NNS
./.
====================
nih/DT
./.
====================
gov/DT
)/)
./.
====================
The/DT
GI50/NN
data/NNS
released/VBD
in/IN
August/NNP
2004/CD
was/VBD
used/VBN
in/IN
this/DT
study/NN
./.
====================
They/PRP
provided/VBD
more/RBR
than/IN
40,000/CD
compounds/NNS
with/IN
a/DT
GI50/NN
value/NN
to/TO
characterize/VB
compound/NN
sensitivity/NN
to/TO
diverse/JJ
NCI60/NN
cancer/NN
cell/NN
lines/NNS
./.
====================
GI50/NN
is/VBZ
defined/VBN
as/IN
the/DT
concentration/NN
of/IN
a/DT
compound/NN
required/VBN
to/TO
inhibit/VB
cell/NN
growth/NN
by/IN
50/CD
%/NN
after/IN
exposed/VBN
to/TO
the/DT
compound/NN
for/IN
48/CD
hours/NNS
in/IN
comparison/NN
with/IN
untreated/JJ
cells/NNS
./.
====================
GI50/NN
values/NNS
were/VBD
further/RBR
transformed/VBN
to/TO
－logGI50/NN
to/TO
linearly/RB
profile/NN
the/DT
compounds/NNS
’/CD
sensitivity/NN
./.
====================
The/DT
2D/NN
structures/NNS
and/CC
chemical/JJ
names/NNS
of/IN
compounds/NNS
were/VBD
also/RB
obtained/VBN
through/IN
the/DT
DTP/NN
website/JJ
of/IN
NCI/NN
./.
====================
Compound/JJ
data/NNS
were/VBD
further/RB
filtered/VBN
based/VBN
upon/IN
several/JJ
criteria/NNS
;/:
the/DT
number/NN
of/IN
missing/VBG
data/NNS
on/IN
60/CD
cell/NN
lines/NNS
＜5/CD
,/,
the/DT
standard/JJ
deviation/NN
(/(
SD/NN
)/)
of/IN
compound/NN
response/NN
＞0.1/NN
,/,
and/CC
－logGI50＞5/NN
in/IN
at/IN
least/JJS
one/CD
cell/NN
line/NN
./.
====================
In/IN
order/NN
to/TO
remove/VB
compounds/NNS
with/IN
many/JJ
missing/JJ
data/NNS
(/(
eg/FW
,/,
GI50/NN
value/NN
)/)
,/,
we/PRP
chose/VBP
compounds/NNS
with/IN
missing/JJ
data/NNS
on/IN
only/RB
less/RBR
than/IN
5/CD
cell/NN
lines/NNS
./.
====================
We/PRP
also/RB
selected/VBN
compounds/NNS
with/IN
relatively/RB
varied/VBN
response/NN
on/IN
diverse/JJ
cell/NN
lines/NNS
by/IN
removing/VBG
compounds/NNS
with/IN
consistent/JJ
response/NN
on/IN
all/DT
60/CD
cell/NN
lines/NNS
(/(
ie/FW
,/,
SD＜0.1/NN
)/)
(/(
Deeken/NN
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Furthermore/RB
,/,
compounds/NNS
with/IN
no/DT
significant/JJ
potency/NN
in/IN
any/DT
cell/NN
lines/NNS
were/VBD
removed/VBN
./.
====================
Thus/RB
,/,
we/PRP
selected/VBD
compounds/NNS
with/IN
－logGI50＞5/NN
(/(
i./FW
e./FW
,/,
GI50＜10μM/NN
)/)
on/IN
at/IN
least/JJS
one/CD
cell/NN
line/NN
./.
====================
NCI60/CD
gene/NN
expression/NN
data/NNS
was/VBD
also/RB
downloaded/VBD
from/IN
the/DT
DTP/NN
website/JJ
./.
====================
NCI60/CD
gene/NN
expression/NN
data/NNS
generated/VBD
using/VBG
Affymetrix/JJ
u133A/B/NN
microarrays/NNS
and/CC
processed/VBN
using/VBG
the/DT
MAS5/NN
normalization/NN
algorithm/NN
(/(
Zhou/NNP
and/CC
Rocke/JJ
,/,
2005/CD
)/)
./.
====================
Data/NNS
for/IN
a/DT
total/JJ
of/IN
44,928/CD
gene/NN
probes/NNS
screened/VBN
on/IN
59/CD
cell/NN
lines/NNS
(/(
data/NNS
missing/VBG
on/IN
NCIH23/NN
cell/NN
line/NN
)/)
were/VBD
retrieved/VBN
./.
====================
Gene/NN
probes/NNS
with/IN
a/DT
standard/JJ
deviation/NN
of/IN
＞2/NN
across/IN
all/DT
59/CD
cell/NN
lines/NNS
and/CC
a/DT
fold/JJ
change/NN
of/IN
＞4/CD
over/IN
the/DT
median/JJ
value/NN
on/IN
at/IN
least/JJS
one/CD
cell/NN
line/NN
were/VBD
selected/VBN
for/IN
the/DT
further/JJ
analysis/NN
./.
====================
Pearson/NN
’/CD
s/NNS
correlation/NN
coefficient/JJ
(/(
PCC/NN
)/)
and/CC
its/PRP$
pvalue/NN
between/IN
compounds/NNS
and/CC
genes/NNS
were/VBD
calculated/VBN
using/VBG
drug/NN
response/NN
and/CC
gene/NN
expression/NN
data/NNS
on/IN
59/CD
NCI60/CD
cell/NN
lines/NNS
./.
====================
The/DT
criteria/NNS
of/IN
PCC＞0.7/NN
and/CC
pvalue＜0.01/NN
were/VBD
applied/VBN
to/TO
select/VB
compoundgene/NN
relationship/NN
for/IN
further/JJ
analysis/NN
./.
====================
Finally/RB
,/,
the/DT
network/NN
was/VBD
constructed/VBN
for/IN
links/NNS
between/IN
compounds/NNS
and/CC
genes/NNS
using/VBG
Cytoscape/NN
(/(
http/NN
:/:
//www/JJ
./.
====================
cytoscape/NN
./.
====================
org//RB
)/)
(/(
Merico/NN
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
The/DT
forcelayout/JJ
algorithm/NN
was/VBD
applied/VBN
to/TO
optimize/VB
the/DT
topology/NN
of/IN
network/NN
(/(
Garcia/FW
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
The/DT
2D/NN
structures/NNS
and/CC
annotation/NN
of/IN
compounds/NNS
were/VBD
displayed/VBN
by/IN
MarvinSketch/NN
developed/VBD
by/IN
ChemAxon/JJ
(/(
http/NN
:/:
//www/JJ
./.
====================
chemaxon/NN
./.
====================
com//RB
)/)
./.
====================
The/DT
structural/JJ
similarity/NN
among/IN
compounds/NNS
was/VBD
calculated/VBN
by/IN
Pipeline/NN
Pilot/NN
(/(
Chu/NNP
et/FW
al./FW
,/,
2009/CD
)/)
./.
====================
Hierarchical/JJ
clustering/NN
of/IN
compound/NN
and/CC
gene/NN
expression/NN
data/NNS
was/VBD
carried/VBN
out/RP
using/VBG
complete/JJ
linkage/NN
algorithm/NN
(/(
Williams/NNS
et/FW
al./FW
,/,
1976/CD
)/)
(/(
http/NN
:/:
//bonsai/LS
./.
====================
hgc/RB
./.
====================
jp/~mdehoon/software/cluster//RB
)/)
./.
====================
Tree/CD
Viewer/JJR
was/VBD
used/VBN
to/TO
visualize/VB
the/DT
clustered/VBN
data/NNS
(/(
http/NN
:/:
//www/JJ
./.
====================
treeview/NN
./.
====================
net/RB
)/)
./.
====================
All/DT
figures/NNS
were/VBD
edited/VBN
using/VBG
Adobe/NN
Illustrator/NN
CS3/NN
(/(
http/NN
:/:
//www/JJ
./.
====================
adobe/NN
./.
====================
com/IN
)/)
./.
====================
Among/IN
48,151/CD
compounds/NNS
,/,
a/DT
total/JJ
of/IN
6,652/CD
compounds/NNS
satisfied/VBD
the/DT
filtration/NN
criteria/NNS
(/(
see/VB
methods/NNS
section/NN
for/IN
details/NNS
)/)
./.
====================
They/PRP
showed/VBD
a/DT
significant/JJ
response/NN
(/(
－logGI50＜5/NN
)/)
on/IN
at/IN
least/JJS
one/CD
cell/NN
lines/NNS
and/CC
demonstrated/VBD
varied/VBN
response/NN
on/IN
60/CD
cell/NN
lines/NNS
with/IN
missing/JJ
data/NNS
on/IN
less/RBR
than/IN
5/CD
cell/NN
lines/NNS
./.
====================
We/PRP
carried/VBD
out/RP
a/DT
clustering/NN
analysis/NN
of/IN
GI50/NN
data/NNS
for/IN
these/DT
6,652/CD
compounds/NNS
over/IN
60/CD
cell/NN
lines/NNS
(/(
Fig/NN
./.
====================
1A/NN
)/)
./.
====================
Three/CD
major/JJ
patterns/NNS
were/VBD
observed/VBN
in/IN
the/DT
com/NN
pound/NN
classification/NN
:/:
sensitive/JJ
or/CC
resistant/JJ
responses/NNS
on/IN
most/JJS
cell/NN
lines/NNS
,/,
and/CC
some/DT
compounds/NNS
exhibiting/VBG
both/CC
sensitive/JJ
and/CC
resistant/JJ
responses/NNS
in/IN
a/DT
cell/NN
linedependent/NN
manner/NN
./.
====================
Many/JJ
of/IN
them/PRP
showed/VBD
a/DT
difference/NN
of/IN
over/IN
＞100-fold/JJ
in/IN
GI50/NN
values/NNS
among/IN
cell/NN
lines/NNS
,/,
which/WDT
implied/VBD
a/DT
cell/NN
line-specific/JJ
mechanism/NN
of/IN
the/DT
drug/NN
action/NN
./.
====================
For/IN
example/NN
,/,
compounds/NNS
in/IN
the/DT
bottom/CC
area/NN
of/IN
the/DT
heatmap/NN
in/IN
Fig/NN
./.
====================
1A/NN
showed/VBD
resistant/JJ
response/NN
(/(
－logGI50=∼－4/NN
)/)
on/IN
most/JJS
cell/NN
lines/NNS
(/(
green/CD
colors/NNS
)/)
,/,
while/IN
a/DT
few/JJ
cell/NN
lines/NNS
gave/VBD
-logGI50＞5/JJ
(/(
red/JJ
colors/NNS
)/)
./.
====================
A/DT
total/JJ
of/IN
9/CD
different/JJ
lineage/NN
groups/NNS
are/VBP
represented/VBN
by/IN
NCI60/CD
cell/NN
lines/NNS
./.
====================
Leukemia/NN
cell/NN
lines/NNS
tended/VBD
to/TO
have/VB
relatively/RB
sensitive/JJ
response/NN
to/TO
the/DT
majority/NN
of/IN
cell/NN
lines/NNS
,/,
although/IN
they/PRP
were/VBD
clustered/VBN
in/IN
two/CD
separate/JJ
groups/NNS
./.
====================
They/PRP
were/VBD
clustered/VBN
together/RB
with/IN
some/DT
lung/NN
cell/NN
lines/NNS
./.
====================
All/DT
of/IN
CNS/NN
cell/NN
lines/NNS
were/VBD
clustered/VBN
together/RB
in/IN
a/DT
large/JJ
group/NN
,/,
and/CC
they/PRP
were/VBD
resistant/JJ
to/TO
more/RBR
numbers/NNS
of/IN
compounds/NNS
than/IN
other/JJ
lineage/NN
groups/NNS
./.
====================
Melanoma/NN
groups/NNS
were/VBD
shown/VBN
to/TO
distribute/VB
in/IN
separate/JJ
clusters/NNS
from/IN
CNS/NN
cell/NN
lines/NNS
./.
====================
Overall/RB
,/,
cell/NN
lines/NNS
did/VBD
not/RB
show/VB
lineage/NN
specific/JJ
clustering/NN
patterns/NNS
of/IN
drug/NN
responses/NNS
;/:
however/RB
,/,
we/PRP
could/MD
find/VB
some/DT
unique/JJ
clustering/NN
patterns/NNS
in/IN
lineage/NN
groups，such/JJ
as/IN
Leukemia/NN
,/,
CNS/NN
and/CC
Melanoma/NN
cells/NNS
./.
====================
Among/IN
6,652/CD
compounds/NNS
with/IN
varied/VBN
responses/NNS
on/IN
NCI60/NN
cell/NN
lines/NNS
,/,
we/PRP
further/RB
selected/VBN
801/CD
compounds/NNS
that/IN
exhibited/VBD
a/DT
significant/JJ
correlation/NN
with/IN
gene/NN
probes/NNS
in/IN
the/DT
DNA/NN
microarray/NN
data/NNS
on/IN
NCI60/NN
cell/NN
lines/NNS
(/(
Fig/NN
./.
====================
1B/NN
)/)
./.
====================
Their/PRP$
GI50/NN
profile/NN
showed/VBD
positive/JJ
or/CC
negative/JJ
correlations/NNS
with/IN
the/DT
expression/NN
profile/NN
of/IN
at/IN
least/JJS
one/CD
gene/NN
probe/NN
in/IN
the/DT
DNA/NN
microarray/NN
data/NNS
./.
====================
We/PRP
focused/VBD
on/IN
these/DT
compounds/NNS
for/IN
the/DT
networkbased/JJ
analysis/NN
of/IN
compound/NN
and/CC
gene/NN
probe/NN
pairs/NNS
./.
====================
In/IN
the/DT
analysis/NN
of/IN
gene/NN
expression/NN
profile/NN
from/IN
DNA/NN
microarray/NN
data/NNS
,/,
lineage-oriented/VBN
clustering/NN
patterns/NNS
were/VBD
more/RBR
obvious/JJ
than/IN
in/IN
the/DT
compound/NN
response/NN
profile/NN
(/(
Fig/NN
./.
====================
2/CD
)/)
./.
====================
We/PRP
used/VBD
a/DT
total/JJ
of/IN
5,635/CD
filtered/JJ
gene/NN
probes/NNS
for/IN
this/DT
analysis/NN
(/(
See/NN
Methods/NNS
section/NN
for/IN
details/NNS
of/IN
filtration/NN
)/)
./.
====================
Among/IN
the/DT
9/CD
different/JJ
lineages/NNS
of/IN
NCI60/NN
cell/NN
lines/NNS
,/,
Leukemia/NN
,/,
CNS/NN
and/CC
colon/NN
cell/NN
lines/NNS
were/VBD
completely/RB
clustered/VBN
together/RB
on/IN
a/DT
lineage/NN
basis/NN
(/(
Fig/NN
./.
====================
2A/NN
)/)
./.
====================
Melanoma/NN
and/CC
Renal/JJ
groups/NNS
were/VBD
also/RB
wellclustered/VBD
with/IN
only/RB
one/CD
exception/NN
./.
====================
Most/JJS
lung/NN
cell/NN
lines/NNS
were/VBD
included/VBN
in/IN
a/DT
single/JJ
cluster/NN
./.
====================
This/DT
observation/NN
was/VBD
roughly/RB
consistent/JJ
with/IN
clustering/NN
patterns/NNS
in/IN
the/DT
compound/NN
response/NN
./.
====================
Relatively/RB
homogeneous/JJ
characteristics/NNS
in/IN
cell/NN
lines/NNS
within/IN
a/DT
lineage/NN
group/NN
(/(
leukemia/NN
,/,
CNS/NN
and/CC
melanoma/NN
)/)
were/VBD
observed/VBN
through/IN
gene/NN
expression/NN
analysis/NN
,/,
which/WDT
explains/VBZ
the/DT
similar/JJ
compound/NN
responses/NNS
among/IN
cell/NN
lines/NNS
of/IN
common/JJ
lineages/NNS
./.
====================
However/RB
,/,
cell/NN
lines/NNS
of/IN
breast/NN
and/CC
ovary/NN
did/VBD
not/RB
show/VB
a/DT
lineageoriented/JJ
clustering/NN
pattern/NN
,/,
indicating/VBG
that/IN
they/PRP
are/VBP
more/RBR
heterogeneous/JJ
than/IN
those/DT
in/IN
other/JJ
lineage/NN
groups/NNS
./.
====================
Thus/RB
,/,
the/DT
analysis/NN
of/IN
compound/NN
responses/NNS
on/IN
these/DT
lineages/NNS
require/VBP
furthers/NNS
sub-clustering/VBG
of/IN
cell/NN
lines/NNS
to/TO
find/VB
improved/VBD
correlations/NNS
between/IN
compound/NN
response/NN
and/CC
gene/NN
expression/NN
profiles/NNS
./.
====================
We/PRP
could/MD
also/RB
identify/VBP
unique/JJ
gene/NN
signatures/NNS
for/IN
several/JJ
lineage/NN
groups/NNS
./.
====================
A/DT
large/JJ
number/NN
of/IN
upregulated/VBN
gene/NN
signatures/NNS
were/VBD
observed/VBN
in/IN
melanoma/NN
cell/NN
lines/NNS
./.
====================
In/IN
the/DT
cases/NNS
of/IN
leukemia/NN
and/CC
colon/NN
cell/NN
lines/NNS
,/,
significant/JJ
gene/NN
signatures/NNS
were/VBD
found/VBN
with/IN
both/CC
up/RB
and/CC
down/RB
regulated/VBN
patterns/NNS
./.
====================
CNS/NN
also/RB
exhibited/VBD
a/DT
small/JJ
lineage-specific/JJ
gene/NN
signature/NN
,/,
while/IN
renal/JJ
cell/NN
lines/NNS
did/VBD
not/RB
show/VB
any/DT
signature/JJ
groups/NNS
with/IN
a/DT
significant/JJ
expression/NN
pattern/NN
./.
====================
Among/IN
these/DT
5,635/CD
gene/NN
probes/NNS
,/,
we/PRP
further/RB
selected/VBN
341/CD
gene/NN
probes/NNS
with/IN
a/DT
significant/JJ
correlation/NN
with/IN
the/DT
GI50/NN
profile/NN
of/IN
a/DT
compound/NN
in/IN
Fig/NN
./.
====================
1/CD
(/(
Fig/NN
./.
====================
2B/NN
)/)
./.
====================
They/PRP
were/VBD
used/VBN
for/IN
the/DT
following/VBG
networkbased/JJ
analysis/NN
./.
====================
In/IN
conclusion/NN
,/,
gene/NN
expression/NN
profiles/NNS
reveal/VBP
lineage/NN
specific/JJ
clustering/NN
patterns/NNS
,/,
indicating/VBG
that/IN
gene/NN
signatures/NNS
effectively/RB
represent/VB
the/DT
distinct/JJ
biological/JJ
features/NNS
in/IN
the/DT
lineage-based/JJ
analysis/NN
of/IN
cell/NN
lines/NNS
./.
====================
In/IN
the/DT
other/JJ
hand/NN
,/,
the/DT
compound/NN
response/NN
data/NNS
shows/VBZ
relatively/RB
complicated/VBN
patterns/NNS
in/IN
the/DT
lineage/NN
clustering/NN
,/,
indicating/VBG
that/IN
the/DT
compound/NN
response/NN
is/VBZ
the/DT
outcome/NN
of/IN
complicated/VBN
mechanisms/NNS
beyond/CC
lineagespecific/JJ
features/NNS
./.
====================
Thus/RB
,/,
combining/VBG
the/DT
GI50/NN
with/IN
gene/NN
expression/NN
data/NNS
on/IN
NCI60/NN
panel/NN
might/MD
provide/VB
a/DT
new/JJ
tool/NN
for/IN
understanding/VBG
lineage-specific/JJ
versus/CC
nonlineagespecific/JJ
mechanisms/NNS
in/IN
drug/NN
action/NN
./.
====================
A/DT
largescale/JJ
correlation/NN
study/NN
between/IN
compound/NN
response/NN
and/CC
gene/NN
expression/NN
was/VBD
carried/VBN
out/RP
using/VBG
NCI60/NN
cell/NN
lines/NNS
./.
====================
The/DT
relationship/NN
was/VBD
analyzed/VBN
on/IN
a/DT
network/NN
which/WDT
represents/VBZ
similarity/NN
of/IN
GI50s/NN
of/IN
a/DT
compound/NN
and/CC
fold/JJ
change/NN
of/IN
a/DT
gene/NN
probe/NN
over/IN
59/CD
cell/NN
lines/NNS
(/(
Fig/NN
./.
====================
3/CD
)/)
./.
====================
Totals/NNS
of/IN
801/CD
compounds/NNS
and/CC
341/CD
gene/NN
probes/NNS
had/VBD
at/IN
least/JJS
one/CD
counterpart/NN
with/IN
a/DT
significantly/RB
high/JJ
correlation/NN
(/(
PCC＞0.7/NN
&/CC
pvalue＜0.01/NN
)/)
./.
====================
Most/JJS
of/IN
the/DT
selected/VBN
gene/NN
probes/NNS
had/VBD
more/RBR
than/IN
one/CD
connected/JJ
compound/NN
that/DT
mediated/VBN
interconnection/NN
among/IN
gene/NN
probes/NNS
,/,
resulting/VBG
in/IN
a/DT
globular/JJ
shape/VBP
in/IN
the/DT
overall/JJ
network/NN
topology/NN
./.
====================
However/RB
,/,
a/DT
small/JJ
number/NN
of/IN
compounds/NNS
and/CC
gene/NN
probes/NNS
showed/VBD
an/DT
isolated/VBN
network/NN
containing/VBG
only/RB
one/CD
or/CC
a/DT
few/JJ
number/NN
of/IN
compoundgene/NN
probe/NN
pairs/NNS
./.
====================
The/DT
data/NNS
provide/VBP
a/DT
useful/JJ
resource/NN
for/IN
studying/VBG
and/CC
predicting/VBG
the/DT
mechanism/NN
of/IN
drug/NN
actions/NNS
on/IN
diverse/JJ
cancer/NN
cells/NNS
./.
====================
To/TO
further/RBR
explore/VB
this/DT
network/NN
,/,
we/PRP
picked/VBD
up/IN
two/CD
subnetworks/NNS
to/TO
examine/VB
the/DT
correlations/NNS
between/IN
the/DT
involved/VBN
components/NNS
./.
====================
Firstly/RB
,/,
as/IN
shown/VBN
in/IN
the/DT
Fig/NN
./.
====================
4/CD
,/,
compound/NN
of/IN
NSC710203/NN
(/(
Obtusol/NN
)/)
shows/VBZ
a/DT
close/JJ
relationship/NN
with/IN
207463_x_at/JJ
,/,
204818_at/JJ
,/,
and/CC
3421_x_at/RB
./.
====================
Obtusol/NN
is/VBZ
known/VBN
to/TO
have/VB
an/DT
antibacterial/JJ
activity/NN
(/(
Vai/NN
rappan/JJ
et/FW
al./FW
,/,
2001/CD
;/:
Vairappan/NN
,/,
2003/CD
)/)
./.
====================
Among/IN
three/CD
related/JJ
gene/NN
probes/NNS
,/,
both/CC
207463_x_at/JJ
,/,
and/CC
3421_/CD
x_at/IN
represent/JJ
the/DT
PRSS3/NN
gene/NN
,/,
which/WDT
can/MD
promotes/VBZ
tumor/NN
growth/NN
and/CC
metastasis/NN
of/IN
human/JJ
pancreatic/JJ
cancer/NN
(/(
Jiang/NNP
et/FW
al./FW
,/,
2010/CD
)/)
./.
====================
Another/DT
gene/NN
probe/NN
204818_at/JJ
is/VBZ
HSD17B2/NN
,/,
which/WDT
can/MD
regulate/VB
intracellular/JJ
levels/NNS
of/IN
granulosa/NN
cells/NNS
(/(
GCs/NNS
)/)
(/(
Svechnikova/NNP
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
These/DT
two/CD
genes/NNS
,/,
PRSS3/NN
and/CC
HSD17B2/NN
are/VBP
predicted/VBN
as/IN
Obtusol/NN
related/JJ
genes/NNS
./.
====================
Interestingly/RB
,/,
Obtusol/NN
showed/VBD
a/DT
relatively/RB
strong/JJ
sensitivity/NN
on/IN
only/RB
a/DT
small/JJ
number/NN
of/IN
colon/NN
cancer/NN
cell/NN
lines/NNS
,/,
while/IN
it/PRP
had/VBD
no/DT
significant/JJ
sensitivity/NN
on/IN
all/DT
of/IN
other/JJ
cell/NN
lines/NNS
(/(
Fig/NN
./.
====================
4B/NN
)/)
./.
====================
The/DT
related/JJ
genes/NNS
,/,
PRSS3/NN
and/CC
HSD17B2/NN
,/,
showed/VBD
a/DT
unique/JJ
upregulation/NN
on/IN
most/JJS
of/IN
colon/NN
cell/NN
lines/NNS
./.
====================
It/PRP
seems/VBZ
that/DT
unique/JJ
functions/NNS
of/IN
these/DT
genes/NNS
in/IN
colon/NN
cancer/NN
cell/NN
lines/NNS
might/MD
be/VB
related/JJ
to/TO
the/DT
mechanism/NN
of/IN
action/NN
of/IN
Obtusol/NN
./.
====================
However/RB
,/,
in/IN
order/NN
to/TO
explain/VB
the/DT
specificity/NN
of/IN
Obtusol/NN
on/IN
a/DT
narrow/JJ
range/NN
of/IN
colon/NN
cell/NN
lines/NNS
,/,
it/PRP
requires/VBZ
further/RBR
sub-classification/NN
of/IN
gene/NN
signatures/NNS
within/IN
the/DT
cell/NN
lines/NNS
of/IN
colon/NN
cancers/NNS
./.
====================
Another/DT
subnetwork/NN
includes/VBZ
a/DT
gene/NN
probe/NN
,/,
209921_/CD
at/IN
,/,
and/CC
a/DT
total/JJ
of/IN
39/CD
related/JJ
compounds/NNS
(/(
Fig/NN
./.
====================
5/CD
)/)
./.
====================
209921_at/RB
presents/VBZ
SLC7A11/NN
(/(
solute/JJ
carrier/NN
family/NN
7/CD
(/(
anionic/JJ
amino/NN
acid/NN
transporter/NN
light/JJ
chain/NN
,/,
xc/JJ
system/NN
)/)
,/,
member/NN
11/CD
)/)
,/,
which/WDT
has/VBZ
been/VBN
known/VBN
as/IN
a/DT
direct/JJ
target/NN
of/IN
miR-26b/JJ
./.
====================
Its/PRP$
expression/NN
is/VBZ
remarkably/RB
increased/VBD
in/IN
both/CC
breast/NN
cancer/NN
cell/NN
lines/NNS
and/CC
clinical/JJ
samples/NNS
(/(
Liu/NNP
et/FW
al./FW
,/,
2011/CD
)/)
./.
====================
MiR-26b/NN
is/VBZ
a/DT
down-regulated/JJ
gene/NN
in/IN
human/JJ
breast/NN
cancer/NN
cell/NN
lines/NNS
which/WDT
can/MD
impairs/VBZ
viability/NN
and/CC
triggers/VBZ
apoptosis/NN
of/IN
human/JJ
MCF7/NN
cells/NNS
(/(
Davoren/NN
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
Based/VBN
on/IN
2D/NN
chemical/JJ
similarity/NN
,/,
27/CD
out/RP
of/IN
39/CD
compounds/NNS
were/VBD
clustered/VBN
into/IN
6/CD
groups/NNS
./.
====================
The/DT
chemical/JJ
names/NNS
of/IN
cluster/NN
centers/NNS
,/,
their/PRP$
biological/JJ
(/(
or/CC
chemical/JJ
)/)
information/NN
and/CC
the/DT
number/NN
of/IN
compounds/NNS
in/IN
each/DT
cluster/NN
were/VBD
summarized/VBN
in/IN
Table/JJ
2/CD
./.
====================
NSC249956/CD
(/(
Chapliatrin/NN
)/)
is/VBZ
isolated/VBN
from/IN
Liatris/NN
gracills/NNS
,/,
which/WDT
has/VBZ
many/JJ
antitumor/JJ
constituents/NNS
(/(
Gravuer/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
NSC34821/NN
(/(
2/CD
Propen1one/NN
,/,
2/CD
[/(
(/(
dimethylamino/NN
)/)
methyl/NN
]/)
1/CD
(/(
2nitro/FW
phenyl/NN
)/)
,/,
hydrochloride/NN
)/)
is/VBZ
a/DT
similar/JJ
chemical/JJ
of/IN
alkylaminopropiophenone/NN
which/WDT
is/VBZ
known/VBN
to/TO
have/VB
a/DT
potent/JJ
antineoplastic/JJ
activity/NN
(/(
Huang/NNP
and/CC
Hall/JJ
,/,
1996/CD
)/)
./.
====================
NSC708044/CD
(/(
2butenoic/JJ
acid/NN
,/,
4,4dicyano4/CD
[/(
(/(
phenylmethylene/NN
)/)
amino/NN
]/)
,/,
methyl/NN
ester/NN
,/,
(/(
Z/NN
,/,
E/NN
)/)
(/(
9CI/CD
)/)
)/)
has/VBZ
an/DT
effect/NN
on/IN
chemoresistance/NN
,/,
mediated/VBN
by/IN
glutathione/NN
transport/VBP
system/NN
(/(
Dai/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
NSC654206/CD
(/(
Naphthsaritone/NN
)/)
and/CC
its/PRP$
related/JJ
compounds/NNS
was/VBD
used/VBN
in/IN
the/DT
treatment/NN
and/CC
control/NN
of/IN
insulin/NN
resistance/NN
and/CC
hyperglycemia/NN
(/(
Cote/NN
and/CC
Goodman/JJ
,/,
1973/CD
)/)
./.
====================
NSC138333/CD
(/(
Cyclohexanone/NN
,/,
2,6bis/DT
(/(
4/CD
(/(
1,3dihydro2Hpyrrolo/JJ
[/(
3,4b/JJ
]/)
quinolin2ylcarbonyl/RB
)/)
2/CD
oxotetrahydro3furanyl/JJ
)/)
methyl/NN
acetate/NN
)/)
,/,
one/CD
of/IN
pyrrolo/JJ
quinoline/RB
derivative/JJ
,/,
is/VBZ
a/DT
potent/JJ
inhibitor/NN
for/IN
PI3kinase/NN
related/JJ
kinases/NNS
(/(
Peng/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
NSC38533/CD
(/(
Cyclohexanone,2,6bis/NN
(/(
4morpholinylmethyl/NN
)/)
,/,
dihydrochloride/NN
)/)
can/MD
be/VB
as/IN
a/DT
potential/JJ
drug/NN
for/IN
the/DT
treatment/NN
of/IN
the/DT
ERnegative/JJ
breast/NN
cancer/NN
MDAMB231/NN
and/CC
SKBr3/NN
human/JJ
breast/NN
cancer/NN
cells/NNS
(/(
SomersEdgar/JJ
et/FW
al./FW
,/,
2011/CD
)/)
./.
====================
It/PRP
is/VBZ
implied/VBN
that/DT
SLC7A11/NN
plays/VBZ
an/DT
essential/JJ
role/NN
in/IN
the/DT
action/NN
of/IN
these/DT
6/CD
compound/NN
classes/NNS
./.
====================
We/PRP
have/VBP
demonstrated/VBN
that/IN
the/DT
networkbased/JJ
analysis/NN
of/IN
compound/NN
response/NN
and/CC
expression/NN
patterns/NNS
is/VBZ
a/DT
new/JJ
promising/JJ
approach/NN
to/TO
categorize/VB
compounds/NNS
and/CC
predict/VBP
the/DT
mechanism/NN
of/IN
action/NN
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
attempted/VBD
to/TO
integrate/VB
compound/NN
and/CC
gene/NN
expression/NN
data/NNS
on/IN
diverse/JJ
cancer/NN
cell/NN
lines/NNS
./.
====================
It/PRP
enabled/VBD
us/PRP
to/TO
find/VB
many/JJ
unexpected/JJ
relationships/NNS
between/IN
genes/NNS
and/CC
compounds/NNS
./.
====================
Previously/RB
,/,
most/JJS
of/IN
analysis/NN
have/VBP
focused/VBN
on/IN
finding/NN
gene/NN
signatures/NNS
(/(
Ballif/NNP
et/FW
al./FW
,/,
2011/CD
)/)
or/CC
compounds/NNS
clusters/NNS
(/(
Takigawa/NNP
et/FW
al./FW
,/,
2011/CD
)/)
,/,
and/CC
there/EX
are/VBP
few/JJ
reports/NNS
on/IN
the/DT
cross/JJ
analysis/NN
of/IN
compound/NN
and/CC
gene/NN
expression/NN
data/NNS
on/IN
diverse/JJ
cell/NN
types/NNS
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
built/VBP
a/DT
network/NN
of/IN
compound/NN
gene/NN
relationships/NNS
on/IN
59/CD
diverse/JJ
cell/NN
lines/NNS
retrieved/VBD
from/IN
NCI60/CD
datasets/NNS
./.
====================
Patterns/NN
in/IN
subnetworks/NNS
provided/VBD
new/JJ
clues/NNS
on/IN
the/DT
possible/JJ
mechanisms/NNS
of/IN
compounds/NNS
./.
====================
This/DT
research/NN
was/VBD
supported/VBN
by/IN
Sookmyung/JJ
Women/NN
’/CD
s/NNS
University/NN
Research/NN
Grants/NNS
110030120/CD
./.
====================
